

# Analysis of *Kras*, *Egfr* and *Tp53* Mutations in F344/NTac Rat and B6C3F1/N Mouse Alveolar/bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt metal

Arun Pandiri

Experimental Pathology Laboratories, Inc.  
Contractor to the National Toxicology Program, NIEHS

NTP Technical Reports Peer Review Meeting  
October 29, 2013

# Introduction

- Mutational patterns of carcinogens
  - Tobacco smoke - Lung cancer (C:G > A:T)
  - Aflatoxin - Hepatocellular carcinoma (C:G > A:T)
  - UV light - Melanoma (C:G > T:A)
  - *H. pylori* - Gastric carcinoma (C:G > T:A)
  - *O. viverrini* - Cholangiocarcinoma (C:G > T:A)
  - Aristolochic acid - Urothelial carcinoma (A:T > T:A)

# Introduction

- “Driver” mutations in genes of human lung cancer
  - *KRAS, EGFR, ALK, ERBB2, BRAF, MAP2K1, PIK3CA, FGFR1, MET, DDR2*
  - *TP53, PTEN, STK11, AKT1*
- Most commonly altered and evaluated mutations in human Non Small Cell Lung Carcinoma (NSCLC) include *KRAS, EGFR* and *TP53*

# Introduction

- Human Non Small Cell Lung Carcinoma (NSCLC)
  - KRAS mutations (26%; 67/254)
  - EGFR mutations (9%; 22/254)
  - TP53 mutations (50%; 52/104)
- *Kras* mutations in Mouse (B6C3F1) lung tumors
  - Spontaneous (27%; 34/124)
  - 1,3-Butadiene (83%; 20/24)
  - Cumene (87%; 45/52)
  - Cobalt sulfate heptahydrate (35%; 9/26)
  - Ethylene oxide (100%; 23/23)

*Sills et al., 1995; Sills et al., 1999; Hong et al., 2007; Hong et al., 2008; Boch et al., 2013; Husgafvel-Pursiainen and Kannio., 1996*

# Objective

Evaluate mutations in *Kras*, *Egfr*, and *Tp53* genes in F344/NTac rat and B6C3F1/N mouse Alveolar/bronchiolar carcinomas (ABCs) arising spontaneously (in controls) and by chronic inhalation exposure to Cobalt metal

## Materials and methods

- DNA was extracted from formalin fixed paraffin embedded (FFPE) ABC tissues from the 2-year bioassay
  - Tumors >5 mm were razor-dissected from five 10 micron FFPE sections
  - If the tumors were microscopic and randomly scattered, then entire FFPE sections were used for DNA extraction
- Semi-nested PCR
  - *Kras* (exons 1 and 2)
  - *Egfr* (exons 18-21)
  - *Tp53* (exons 5-8)
- Amplified DNA purified and Sanger sequenced (2x)
- Samples with mutations were confirmed by repeat analysis starting with the original DNA extracts.

# Results

## Rat ABC mutation analysis

Cobalt metal	n	Mutation Frequency		
		<i>Kras</i>	<i>Egfr</i>	<i>Tp53</i>
Control#	10	0 (0%)**	0 (0%)	0 (0%)
1.25 mg/m <sup>3</sup>	14	2 (14%)	2 (14%)	3 (21%)
2.5 mg/m <sup>3</sup>	17	6 (35%)*	3 (18%)	6 (35%)*
5 mg/m <sup>3</sup>	17	7 (41%)*	3 (18%)	2 (12%)
<b>Treated Total</b>	<b>48</b>	<b>15 (31%)*</b>	<b>8 (17%)</b>	<b>11 (23%)</b>

\* Significantly different ( $P \leq 0.05$ ) from the chamber control group by the Fisher's exact test

\*\* Significant trend ( $P \leq 0.001$ ) by the Cochran-Armitage trend test

# Spontaneous alveolar/bronchiolar carcinomas (n=10) were sourced from vehicle or chamber control groups in various NTP chronic bioassays.

# Results

## Mouse ABC mutation analysis

Cobalt metal	n	Mutation Frequency		
		<i>Kras</i>	<i>Egfr</i>	<i>Tp53</i>
Historical control <sup>#</sup>	124	34 (27%)	NA	NA
Control	10	0 (0%) <sup>###</sup>	0 (0%)	0 (0%)
1.25 mg/m <sup>3</sup>	16	11 (69%) <sup>***</sup>	2 (13%)	3 (19%)
2.5 mg/m <sup>3</sup>	23	11 (48%) <sup>**</sup>	7 (30%)	3 (13%)
5 mg/m <sup>3</sup>	30	24 (80%) <sup>***</sup>	3 (10%)	7 (23%)
<b>Treated Total</b>	<b>69</b>	<b>46 (67%)<sup>***</sup></b>	<b>12 (17%)</b>	<b>13 (19%)</b>

\*\* Significantly different ( $P \leq 0.01$ ) from the chamber control group by the Fischer's exact test

\*\*\*  $P \leq 0.001$  by one-sided Fischer exact test for single or combined exposure groups or a one-sided Cochran-Armitage trend test for the chamber control group

### Significant trend ( $P \leq 0.001$ ) by the Cochran-Armitage trend test

# All routes, all vehicles; NA = not available



# Results

- ***Kras* mutations**

- Rats (n=15): codon 12 (93%) > codon 13 (7%)
- Mice (n=48\*): codon 12 (63%) > codon 61 (29%) > codon 13 (8%)
- Mice historical control spontaneous ABC (n=34)
  - codon 12 (59%) > codon 61 (23%) > codon 13 (18%)

- ***Egfr* mutations**

- Rats (n=9\*): exon 20 (67%) > exon 21 (22%) > exon 19 (11%)
- Mice (n=12): exon 20 (50%) > exon 21 (33%) > exon 18 & 19 (8%)

- ***Tp53* mutations**

- Rats (n=13\*): exon 6 (38%) > exon 7 and 8 (23%) > exon 5 (15%)
- Mice (n=14\*): exon 5 (50%) > exon 7 (29%) > exon 6 (21%)

\* *Double mutations included*

# Results

- ***Kras* mutations**

- Rats: G→T transversions (57%; 8/14) and G→A transitions (43%; 6/14)
- Mice: G→T transversions (80%; 24/30) and G→A transitions (17%; 5/30)
- Mice historical spontaneous ABC (n=124): G→A transition (70%; 14/20)

- ***Egfr* mutations**

- Rats: Transitions G→A (50%; 5/10) or C→T (30%; 3/10)
- Mice: Transitions G→A (42%; 5/12) or C→T (17%; 2/12)

- ***Tp53* mutations**

- Rats: Transitions C→T (38%; 5/13) or G→A (31%; 4/13)
- Mice: Transversions G→C (60%; 9/15)

# Discussion

- *Kras* Codon 12 mutations were the most common mutations in rat and mouse ABCs resulting from cobalt metal exposure
  - human NSCLC contains *KRAS* mutations in codons 12 (86%) and 13 (14%)
- G→T transversions were the most common mutations in cobalt metal exposed rat (57%) and mouse (80%) ABCs
  - one of the most common mutations in mouse (55%) ABCs resulting from cobalt sulfate heptahydrate aerosol inhalation exposure (NTP TR 471)
  - one of the most common mutations in human (67%) NSCLC
  - correlate with 8-OHdG adducts resulting from oxidative stress

*Sills et al., 1998 in NTP TR 471; Devereux et al., 1993; Rodenhuis et al., 1989; Siegfried et al., 1997*

# Acknowledgements

- Lily Hong
- Mark Hoenerhoff
- Ronald Herbert
- Robert Sills
- Michelle Hooth
- Mamta Behl
- Grace Kissling
- Kristine Witt
- NIEHS sequencing core